The company's gene-editing-focused platform looks promising.
Artificial intelligence has fundamentally reshaped drug discovery, accelerating target identification, decoding ...
Isaacson argues that who patents, regulates, and profits from gene editing now matters as much as the science, because rewriting human heredity is no longer theoretical.
Dublin, Oct. 22, 2026 (GLOBE NEWSWIRE) -- "Automatic Nucleic Acid Synthesizer Market: Strategic Trends, Industry Dynamics, and Forecasts" has been added to ResearchAndMarkets.com's offering. The ...
ERS Genomics Limited ('ERS Genomics'), the CRISPR licensing company, today announced that it has signed a non-exclusive ...
New Cellgorithm™ data presented at ISSCR symposium indicates faster, scalable cell programming and add to Syntax Bio’s ...
CCT, CGC Landran organizes national workshop on CRISPR-Cas, AI and Biotechnology ...
A 2026 review describes CRISPR-Cas as a promising strategy for addressing drug-resistant Pseudomonas aeruginosa infections ...
A 2026 review summarizes advances in CRISPR-Cas9 precision, delivery and primary-cell engineering for genetic diseases and ...
Myllia Biotechnology, a specialist in high-content CRISPR screens in primary human cells, today announced the formation of ...
In this interview, Prof. Samuel Sternberg discusses how studies of CRISPR-Cas systems led to the discovery of RNA-guided DNA ...
When Japanese researchers at the University of Yamanashi cloned mice through 58 consecutive generations this year — watching ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results